Celularity FY23 Revenue Of $22.8M; Sees Q1 Revenue $14.8M; Expected Combined Net Sales For The First Half 2024 Are $25.8M-$27.8M
Portfolio Pulse from Benzinga Newsdesk
Celularity Inc. (NASDAQ: CELU) reported FY23 revenue of $22.8M, exceeding expectations. The company projects Q1 2024 revenue of $14.8M, significantly higher than previous guidance. Expected combined net sales for H1 2024 are $25.8M-$27.8M, a substantial increase from H1 2023. Celularity is also on track to file a 510(k) premarket submission for its Celularity Tendon Wrap in H2 2025.
July 31, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celularity Inc. reported FY23 revenue of $22.8M, exceeding expectations. The company projects Q1 2024 revenue of $14.8M, significantly higher than previous guidance. Expected combined net sales for H1 2024 are $25.8M-$27.8M, a substantial increase from H1 2023. Celularity is also on track to file a 510(k) premarket submission for its Celularity Tendon Wrap in H2 2025.
Celularity's FY23 revenue exceeded expectations, and the company has provided strong guidance for Q1 and H1 2024. This positive financial performance and outlook are likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100